Replies to post #150805 on Bioelectronics Corp (BIEL)

[purdue pete]

i am hoping AW said "with exceptional growth" at the end of the interview and not "with the exception of growth"....it is tough to understand....

[Tropicalstocks]

I got my feet up and my hands behind my head. BIEL anyday now!

[srinsocal]

Thanks DB, I thought this was AW's best interview effort in a couple of years. He kept on message and quoted numerous stats w/o hesitation.

Mundipharma:

Adding 5 countries in addition to Australia and New Zealand

Malesia
Thailand
Indonesia
Singapore
Philippines

"We're working on getting them to expand"

Dr. Scholl's:

"Dr. Scholl's is moving along"
"It's negotiations with giants and they just take time"
"But I would say it is moving well"

FDA Back 510k:

No comments or questions received from FDA

"Moving along at a good pace"

Pipeline:

"But we also have significant opportunities in Menstrual Pain, Overactive Bladder, and the list goes on"

"We will be an extremely busy company over the next couple of years"


US Sales:

"Pretty confident we're going to be able to get a partner"

AW goes on to explain that rather than spending money on promoting a "Knee" product, with 25 million potential users, he feels it is better to save company resources for the Full Musculoskeletal Clearance which will increase potential users to 125 million.

Opioid Innovation Challenge:

"I think it is extremely important" "Definitely be transformative for the company"

The UK Study shows that ActiPatch can reduce or eliminate Opioid use

New Deals:

(while discussing Dr. Scholl's) "We had another group that came in that we think will give us very broad coverage on the ActiPatch product and possibly the Allay product"

(While discussing Mundipharma) "Opened dialogue with a group doing Eastern Europe"

Final Words:

Host: "I hope that you come back on the show in another 40-50 days and give us an update on that 510"

AW: "I don't want to give you an update, I want to tell you it's done"

https://upticknewswire.com/featured-interview-ceo-andrew-whelan-of-bioelectronics-corp-otc-pink-biel-4/